MEGIN and BESA Open Brain Imaging Architecture for the AI Era

HELSINKI and GRÄFELFING, Germany – May 12, 2026 – In a move poised to accelerate the integration of artificial intelligence into neuroscience, magnetoencephalography (MEG) leader MEGIN and brain analysis software specialist BESA GmbH have announced a significant expansion of their strategic partnership. The agreement establishes an open platform architecture designed to bring advanced AI and computational tools into the mainstream of clinical and research brain imaging.

This renewed collaboration deepens a decade-long relationship that has already shaped the modern MEG landscape, most notably through the joint development of the MEG Maps™ platform. By creating a shared, open framework, the two companies aim to solve a critical challenge facing the field: how to incorporate a wave of new AI-driven technologies without disrupting the complex workflows of clinicians and researchers.

A New Blueprint for Neuro-Innovation

Magnetoencephalography is a non-invasive neuroimaging technique that provides a uniquely powerful view of brain function, capturing neural activity with millisecond precision. It is a critical tool for localizing epileptic activity before surgery, mapping brain function for surgical planning, and conducting advanced neuroscience research. MEGIN, with its flagship TRIUX™ neo system, is the dominant force in this market.

However, the raw data produced by MEG systems is incredibly complex. Its clinical value is unlocked through sophisticated analysis software, which is where BESA has established itself as a world leader for over 30 years. The new agreement formalizes an 'open by design' philosophy, creating a standardized pathway for new analytical tools—especially those powered by AI—to be integrated into the MEGIN ecosystem.

“Our partnership with BESA has shaped the modern clinical MEG workflow, and MEG Maps is an example of what our two companies can build together,” said Gordon Baltzer, President of MEGIN. “This renewed agreement takes that foundation and opens it up. The pace of change in AI and computational neuroscience requires a framework that is open by design, and MEGIN’s role as the industry leader is to remove the roadblocks that prevent the field from adopting valuable new technologies.”

Under the terms, all new MEGIN customers will gain access to the BESA Research software suite. More importantly, the partnership will define a clear process for vetting and integrating emerging AI capabilities as they mature, ensuring they can be deployed reliably and at scale across the global MEG community.

“What began as a development collaboration has matured into a true strategic alignment,” noted Dr. Tobias Scherg, Chief Executive Officer of BESA GmbH. “Together, BESA and MEGIN have already changed what is possible in clinical and research MEG, and this renewed agreement reflects our shared conviction that the next chapter, defined by AI-enabled analysis and emerging computational technologies, must be built on an open, integrated platform.”

Navigating the Complexities of AI in Medicine

The announcement comes at a pivotal moment for artificial intelligence in healthcare. While the potential of AI to revolutionize diagnostics and treatment is immense, its practical adoption in clinical settings is fraught with challenges. Many AI models are criticized for being 'black boxes,' with internal decision-making processes that are opaque to clinicians and regulators. Furthermore, integrating standalone AI solutions into established hospital IT systems and clinical workflows often proves to be a major technical and logistical hurdle.

The MEGIN-BESA strategy directly confronts this integration problem. By creating a unified platform, they aim to provide a consistent environment where new tools can be added without fracturing the user experience. This approach could be crucial for building clinician trust and lowering the barrier to adoption.

Beyond workflow, the partnership will have to navigate a formidable regulatory landscape. Medical devices powered by AI face intense scrutiny from bodies like the U.S. Food and Drug Administration (FDA) and European authorities under the new Medical Device Regulation (MDR). Regulators are grappling with how to approve adaptive algorithms that can learn and change over time, a stark departure from traditional static medical devices. Demonstrating the safety, efficacy, and lack of bias in these advanced systems will be a key challenge for the joint development pipeline MEGIN and BESA plan to unveil in the coming months.

An Ecosystem Over an Empire

This move also reflects a broader strategic shift in the competitive medical technology market, where walled-garden ecosystems are giving way to more collaborative, open models. In recent years, similar partnerships have emerged across the medical imaging sector, with major players like Philips and Arterys creating platforms that integrate third-party AI solutions. This trend acknowledges that no single company can master the full spectrum of innovation in the fast-moving AI space.

By committing to an open architecture, MEGIN and BESA are positioning themselves not just as vendors, but as facilitators of a broader innovation ecosystem. This could attract third-party AI developers, academic research labs, and other technology providers to build on their platform, potentially accelerating the pace of discovery and development for the entire field.

The endorsement from a prominent clinical leader underscores the potential of this approach. “Bringing together MEGIN's clinical MEG expertise with BESA's advanced analytical capabilities within a more open framework is an important step toward a more consistent and practical ecosystem for clinical MEG,” commented Timothy P.L. Roberts, PhD, Director of the Lurie Family Foundations MEG Imaging Center at the Children’s Hospital of Philadelphia.

The Path to Better Patient Outcomes

Ultimately, the success of this partnership will be measured by its impact on patients. For individuals with neurological conditions like epilepsy, brain tumors, or traumatic brain injury, the precision of diagnostic imaging can be life-changing. AI promises to make the analysis of complex MEG data faster, more accurate, and more objective.

For example, in pre-surgical planning for epilepsy, AI could help clinicians pinpoint the source of seizures with greater confidence, leading to more effective surgeries with fewer side effects. In traumatic brain injury, advanced computational analysis may one day identify subtle patterns of brain dysfunction that are invisible to the naked eye, enabling earlier and more targeted interventions.

By standardizing the integration of these advanced tools, the MEGIN-BESA platform aims to make cutting-edge analysis more accessible to a wider range of hospitals and research centers, moving powerful new techniques from specialized academic labs into routine clinical practice. The companies have assured existing customers of continuity while promising to share further details on their joint AI-enabled development pipeline in the near future, signaling that the AI-era of brain imaging is not just a concept, but an active and accelerating reality.